Propanc Biopharma’s peer-reviewed papers on proenzyme cancer treatment generate ‘unprecedented’ interest Page 1

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurrent and metastatic cancer, today announced that two scientific, peer-reviewed journal articles published by the Company and its research partners achieved 10 citations and 4,500 reads, respectively, in August 2024. “This demonstrates unprecedented interest in our field from researchers and within the broader scientific community,” said Dr. Kenyon, MD, MB, ChB, Chief Scientific Officer of Propanc.

The first article, which reached 10 citations and was published in Scientific Reports, is entitled: “Treatment with pancreatic proenzymes suppresses the BXPC-3 subpopulation of pancreatic cancer stem cells and impedes tumor engraftment.”From the publishers of Nature, it is an online, open access journal, publishing from all areas of the natural and clinical sciences. According to an insider, Scientific Reports is published on the most prestigious site of the National Institute of Health (NIH) and is considered top line coverage: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684636/